

## 町田 治彦 発表論文・総説・プロシーディングー覧：ジャンル別

### 【第 I 部：抗ウイルス剤／ソリブジン関係】

- 1) Machida H, Sakata S, Kuninaka A, Yoshino H, Nakayama C, Saneyoshi M. In vitro antiherpesviral activity of 5-alkyl derivatives of 1- $\beta$ -D-arabinofuranosyluracil. *Antimicrob Agents Chemother* 16: 158-163, 1979.
- 2) Machida H, Ichikawa M, Kuninaka A, Saneyoshi M, Yoshino H. Effect of treatment with 1- $\beta$ -D-arabinofuranosylthymine of experimental encephalitis induced by herpes simplex virus in mice. *Antimicrob Agents Chemother* 17: 109-114, 1980.
- 3) Machida H, Kuninaka A, Yoshino H, Ikeda I, Mizuno H. Antiherpesviral activity and inhibitory action on cell growth of 5-alkenyl derivatives of 1- $\beta$ -D-arabinofuranosyluracil. *Antimicrob Agents Chemother* 17: 1030-1031, 1980.
- 4) Machida H, Sakata S, Kuninaka A, Yoshino H. Antiherpesviral and anticellular effects of 1- $\beta$ -D-arabinofuranosyl-E-5-(2-halogenovinyl)uracils. *Antimicrob Agents Chemother* 20: 47-52, 1981.
- 5) Machida H, Kuninaka A, Yoshino H. Inhibitory effect of antiherpesviral thymidine analogs against varicella-zoster virus. *Antimicrob Agents Chemother* 21: 358-361, 1982.
- 6) Machida H, Sakata S, Morozumi M, Kiyonagi T, Kuninaka A, Yoshino H. Comparison of in vitro and in vivo anti-herpes activities of 1- $\beta$ -D-arabinofuranosylthymine and its 5'-monophosphate. *Antiviral Res* 2: 217-226, 1982.
- 7) Machida H, Sakata S. In vitro and in vivo antiviral activity of 1- $\beta$ -D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds. *Antiviral Res* 4: 135-141, 1984.
- 8) Machida H. Susceptibility of varicella-zoster virus to thymidine analogs. *Biken Journal* 29: 1-6, 1986.
- 9) Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex virus to nucleoside analogs. *Antimicrob Agents Chemother* 29: 524-526, 1986.
- 10) 町田 治彦 新規抗ウイルス剤, ブロバビル (BV-アラ U) の *in vitro* 抗ヘルペス作用 *Chemotherapy* 38: 256-261, 1990.
- 11) Machida H, Ikeda T, Ashida N. Comparison of antiviral efficacies of 1- $\beta$ -D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and acyclovir against herpes simplex virus type 1 infection in mice. *Antiviral Res* 14: 99-107, 1990.
- 12) Machida H, Takezawa J. Effect of 1- $\beta$ -D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (Brovavir) on experimental infections in mice with herpes simplex virus type 1 strains of different degree of virulence. *Antimicrob Agents Chemother* 34: 691-696, 1990.

- 13) Machida H, Nishitani M. Drug Susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. *Microbiol Immunol* 34: 407-411, 1990.
- 14) Machida H, Ijichi K, Ohta A, Honda M, Niimura M. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines. *Microbiol Immunol* 34: 959-965, 1990.
- 15) Machida H, Watanabe Y. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU. *Microbiol Immunol* 35: 139-145, 1991.
- 16) Machida H, Nishitani M, Suzutani T, Hayashi K. Different antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells. *Microbiol Immunol* 35: 963-973, 1991.
- 17) Machida H, Ijichi K, Takezawa J. Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice. *Antiviral Res* 17: 133-143, 1992.
- 18) Machida H, Ashida N, Ikeda T, Sakata S, Baba M, Shigeta S. In vitro drug combination of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides. *Antimicrob Agents Chemother* 36: 214-216, 1992.
- 19) Machida H, Sakata S, Ashida N, Takeuki K, Matsuda A. *In vitro* antiherpesvirus activities of 5-substitued 2'-deoxy-2'-methyliden pyrimidine nucleoside. *Antiviral Chem Chemother*. 4: 11-17, 1993.
- 20) Machida H, Nishitani M, Ashida N. Effect of BV-araU ad acyclovir on varicella-zoster virus replication with various length and timing of drug exposure. *Microbiol Immunol* 38: 109-115, 1994.
- 21) Machida H, Nishitani M, Watanabe Y, Yoshimura Y, Kano F, Sakata S. Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogs. *Microbiol Immunol* 39: 201-206, 1995.
- 22) Machida H, Watanabe Y, Kano F, Sakata S, Kumagai M, Yamaguchi T. Deglycosylation of antiherpesviral 5-substitued arabinosyluracil derivatives by rat liver extract and enterobacteria cells. *Biochem Pharmacol* 49: 763-766, 1995.
- 23) Machida H, Ashida N, Miura S, Endo M, Yamada K, Kitano K, Yoshimura Y, Sakata S, Ijichi O, Eizuru Y. Anti-herpesvirus activity profile of 4'-thio-arabinofuranosyl purine and uracil nucleosides and activity of 1- $\beta$ -D-2'-fluoro- 4'-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus. *Antiviral Res* 39: 129-137, 1998.
- 24) Cheng Y-C, Dutschman G, Fox JJ, Watanabe KA, Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. *Antimicrob Agents Chemother* 20: 420-423, 1981.

- 25) Suzuki S, Machida H, Saneyoshi M. Antiviral activities of various 1- $\beta$ -D-arabinofuranosyl-*E*-5-halogenovinyluracils and *E*-5-bromovinyl-2'-deoxyuridine against salmon herpes virus, *Oncorhynchus masou* virus (OMV). *Antiviral Res* 7: 79-86, 1987.
- 26) Ayisi N, K, Wall R, A, Wanklin R, J, Machida H, De Clercq E, Sacks S, L. Comparative metabolism of *E*-5-(2-bromovinyl)-2'-deoxyuridine and 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells. *Mol Pharmacol* 31: 422-429, 1987.
- 27) Suzutani T, Machida H, Sakuma T. Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells. *Antimicrob Agents Chemother* 32: 1046-1052, 1988.
- 28) Lin J-C, Machida H. Comparison of two bromovinyl nucleoside analogs, 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl) uracil and *E*-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. *Antimicrob Agents Chemother* 32: 1068-1072, 1988.
- 29) Suzutani T, Machida H, Sakuma T, Azuma M. Effects of various nucleosides on antiviral activity and metabolism of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2. *Antimicrob Agents Chemother* 32: 1547-1551, 1988.
- 30) Yokota T, Kono K, Mori S, Shigeta S, Kumagai M, Watanabe Y, Machida H. Mechanism of selective inhibition of varicella-zoster virus replication by 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil. *Molec Pharmacol* 36: 312-316, 1989.
- 31) Ijichi K, Ashida N, Machida H. Effect of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)-uracil against herpes simplex virus type 1 infection in immunosuppressed mice. *Antimicrob Agents Chemother* 34: 2431-2433, 1990.
- 32) 熊谷 眞男, 坂田 紳二, 山口 十四文, 稲葉 勲, 小池 一弘, 町田 治彦 プロバビル (YN-72)の物理化学的性質 *医薬品研究* 21: 574-583, 1990.
- 33) Suzutani T, Machida H. Analysis of toxic and mutagenic activities of antiherpesvirus nucleosides against HeLa cells and herpes simplex virus type 1. *Mutation Res* 267: 125-131, 1992.
- 34) Ijichi K, Ashida N, Varia, S, Machida H. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1. *Antiviral Res* 21: 47-57, 1993.
- 35) Suzutani T, Machida H, Honess RW. Mechanism of inhibition of DNA synthesis by 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil. *Microbiol Immunol* 37: 511-513, 1993.
- 36) Ashida N, Ijichi K, Watanabe Y, Machida H. Metabolism of 5'-ethet prodrugs of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil in rats. *Biochem Pharmacol* 46: 2201-2207, 1993.

- 37) Ashida N, Sakata S, Kano F, Nishitani M, Watanabe Y, Machida H. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU. *Antiviral Res* 25: 179-184, 1994.
- 38) Mochizuki K, Torisaki M, Yamashita Y, Komatsu M, Tanahashi T, Ijichi K, Machida H. Retinal toxicity and ocular kinetics of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil in rabbits. *Graefe's Arch Clin Exp Ophthalmol* 232: 503-508, 1994.
- 39) Ijichi K, Fujiwara M, Mori K, Morozumi M, Machida H, Shigeta S, Konno K, Yokota T, Baba M. Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. *Antiviral Res* 31: 115-120, 1996.
- 40) Ashida N, Watanabe Y, Miura S, Kano F, Sakata S, Yamaguchi T, Suzutani T, Machida H. Structure-activity relationship of the affinity of 5-substituted uracil nucleosides for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus. *Antiviral Res* 35: 167-175, 1997.
- 41) Ashida N, Sakata S, Machida H. Metabolic fate of [<sup>3</sup>H]1- $\beta$ -D-arabinofuranosyl-5-[(*E*)-2-bromovinyl]uracil in herpes simplex virus type 1-infected cells. *Microbiol Immunol* 41: 957-964, 1997.
- 42) Manfredini S, Baraldi P G, Bazzanini R, Bortolotti F, Vertuani S, Ashida N, Machida H. Enzymatic synthesis of 5'-*O*-acyl prodrugs of 1-( $\beta$ -D-arabinofuranosyl)-5(*E*)-(2-bromovinyl)uracil and of 2'-*O*-acyl-araU, -araC and araA. *Antiviral Chem Chemother* 9: 25-31, 1998.
- 43) Fujiwara M, Okamoto M, Okamoto M, Watanabe M, Machida H, Shigeta S, Konno K, Yokota T, Baba M. Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells. *Antiviral Res* 43: 189-199, 1999.
- 44) Ashida N, Machida H. Anti-herpesvirus activity profile of 4'-thio-arabinofuranosyl nucleoside analogues. *Recent Devel Antiviral Res* 1: 63-73, 2001.
- 45) Kodama E, Kohgo S, Kitano K, Machida H, Gataganaga H, Shigeta S, Matsuoka M, Ohrai H, Mitsuhashi H. 4'-Ethyne nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variant in vitro. *Antimicrob Agents Chemother* 45: 1539-1546, 2001.

Proceedings of Symposium:

- 1) Machida H, Sakata S, Shibuya S, Ikeda I, Nakayama C, Saneyoshi M. Selective antiherpesviral activity of 5-substituted derivatives of 1- $\beta$ -D-arabinofuranosyluracil. *In Antiviral Chemotherapy: Design of inhibitors of viral infections*, edited by K K Gauri, Academic Press, Inc., New York, pp207-217, 1981.
- 2) Machida H, Sakata S, Kuninaka A, Yoshino H. *In vitro* and *in vivo* anti-HSV activities of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-halogenovinyl)uracil. *In Herpesvirus: Clinical*,

pharmacological and basic aspects, edited by H Shiota, Y-C Cheng, W H Prusoff. Excerpta Medica, Amsterdam, pp165-174, 1982.

- 3) Machida H, Kuninaka A, Yoshino H. Susceptibility of several strains of varicella-zoster virus to 5-substituted derivatives of 2'-deoxyuridine and 1- $\beta$ -D-arabinofuranosyluracil. In Herpesvirus: Clinical, pharmacological and basic aspects, edited by H Shiota, Y-C Cheng, W H Prusoff. Excerpta Medica, Amsterdam, pp223-226, 1982.
- 4) Machida H, Sakata S, Saito K. Bromovinyl-arabiosyluracil (BV-araU): Antiviral activity and pharmacology. In Herpesviruses and virus chemotherapy. Pharmacological and clinical approaches, edited by R Kono, A Nakajima. Excerpta Medica, Amsterdam, pp63-65, 1985.
- 5) Machida H, Abiru T, Ikeda T. Selective anti-herpesvirus activity of BV-araU. In Recent advances in chemotherapy. Antimicrobial section, edited by J Ishigami. University of Tokyo Press, Tokyo, pp1959-1960, 1985.
- 6) Machida H. Brovavir: Its antiherpesviral activity and mode of action. In Immunology and prophylaxis of human Herpesvirus infections, edited by C Lopes, R Mori, B Roizman, R Whitely. Excerpta Medica, Amsterdam, pp255-265, 1990.
- 7) Saito K, Machida H, Kuninaka A, Yoshino H, Miyasaka M, Kawamura H, Ito R. Safety of 1- $\beta$ -D-arabinofuranosylthymine in toxicity and teratogenicity in rats. In Herpesvirus: Clinical, pharmacological and basic aspects, edited by H Shiota, Y-C Cheng, W H Prusoff. Excerpta Medica, Amsterdam, pp219-222, 1982.
- 8) Lin J-C, Machida H. Inhibition of Epstein-Barr virus replication by 1- $\beta$ -D-arabinofuranosyl-E-5-(2-bromovinyl)uracil *in vitro*. In Epstein-Barr virus and human diseases, edited by P H Levine, D V Ablashi, M Nonoyama, G R Person, R Glaser. The Humana Press, Clifton, New Jersey, pp497-502, 1987.

Review articles :

- 1) Machida H, Sakata S. BVAU. Drugs of the future VII, 458-459, 1982.
- 2) 町田 治彦 新しい抗ヘルペス剤 —高選択性抗ウイルス剤の開発 医学のあゆみ 146: 73-76, 1988.
- 3) 町田 治彦 抗ウイルス剤の作用機序 ファルマシア 24: 49-53, 1988.
- 4) 町田 治彦 ウイルス感染症の化学療法 Medical Immunology 17: 313-320, 1989.
- 5) 町田 治彦 抗ウイルス剤 現代化学 1989年3月号: 56-61.
- 6) 町田 治彦 抗ウイルス剤の研究開発 化学と生物 27: 356-366, 1989.
- 7) 町田 治彦 ウイルス化学療法剤開発の問題点 臨床と微生物 18: 619-624, 1991.
- 8) 町田 治彦 新しい抗ヘルペスウイルス剤 これからの単純疱疹, 帯状疱疹, 水痘の薬 ファルマシア 29: 1137-1139, 1993.
- 9) 町田 治彦 単純ヘルペス, 水痘, 帯状疱疹に対する新しい抗ヘルペス剤 医学のあゆみ 167: 220, 1993.

- 10) Machida H, Sakata S. 5-Substituted arabinofuranosyluracil nucleoside as anti herpesvirus agents: From araT to BV-araU. *In* Nucleosides and nucleotides as antitumor and antiviral agents, edited by C K Chu, D C Baker. Plenum Press, New York, pp245-264, 1993.
- 11) 町田 治彦 薬学からみたヘルペス感染症 —化学療法への最近のアプローチ 臨牀と研究 71: 2093-2097, 1994.
- 12) 町田 治彦 抗ヘルペス剤 *Molecular Medicine* 32: 1032-1039, 1995.
- 13) 町田 治彦 抗ヘルペス剤開発の進歩 *Bio Clinica* 16: 1201-1206, 2001.
- 14) Rabasseda X, Mealy N, Machida H. Sorivudine: A New antiviral drug specifically active against herpes simplex virus type 1 and varicella-zoster. *Drugs of today* 29: 555-567, 1993.

## 【第Ⅱ部:抗ウイルス剤以外】

### Ⅱ-1 微生物／酵素関係

- 1) Machida H, Kuninaka A. Studies on the accumulation of orotic acid by *Escherichia coli* K 12. *Agirc Biol Chem* 33: 868-875, 1969.
- 2) Machida H, Kuninaka A, Yoshino H. Studies on the accumulation of orotic acid by *Escherichia coli* K 12. Part II. Mechanism of the accumulation. *Agirc Biol Chem* 34: 1129-1135, 1970.
- 3) Kusakabe H, Kodama K, Midorikawa Y, Machida H, Kuninaka A, Yoshino H. Inhibition of growth of L5178Y Leukemia cells by fugal folate-deaminating enzyme. *Agirc Biol Chem* 38: 1753-1754, 1974.
- 4) Kusakabe H, Kodama K, Machida H, Midorikawa Y, Kuninaka A, Misono H, Soda K. Occurrence of a novel enzyme, L-lysine oxidase with antitumor activity in culture extract of *Tricoderma viride*. *Agirc Biol Chem* 43: 337-343, 1979.
- 5) Kusakabe H, Kodama K, Machida H, Kuninaka A. Antitumor activity of a pterin deaminase. *Agirc Biol Chem* 43: 1983-1984, 1979.
- 6) Kodama K, Kusakabe H, Machida H, Midorikawa Y, Shibuya S, Kuninaka A, Yoshino H. Isolation of 2'-deoxycoformycin and cordycepin from wheat bran culture of *Aspergillus nidulans* Y 176-2. *Agirc Biol Chem* 43: 2375-2377, 1979.
- 7) Yamauchi H, Machida H, Midorikawa Y, Kuninaka A. Immobilization of polynucleotide phosphorylase on inorganic support. *J Ferment Technol* 64: 455-457, 1986.
- 8) Yamauchi H, Machida H. Continuous production of homopolynucleotides by immobilized polynucleotide phosphorylase. *J Ferment Technol* 64: 517-522, 1986.

### Ⅱ-2 植物ウイルス関係

- 1) Machida H, Hayashi T, Abe T, Kiho Y. *In vivo* uncoating of tobacco mosaic virus after infection of tobacco leaves. *Japan J Microbiol* 13: 351-357, 1969.

- 2) Machida H, Kiho Y. *In vivo* uncoating of tobacco mosaic virus II. Complete uncoating to TMV-RNA. Japan J Microbiol 14: 441-449, 1970.
- 3) Hayashi T, Machida H, Abe T, Kiho Y. *In vivo* uncoating of tobacco mosaic virus irradiated with ultraviolet light. Japan J Microbiol 13: 386-387, 1969.
- 4) Kiho Y, Machida H, Oshima N. Mechanism determining the host specificity of tobacco mosaic virus I. Formation of polysomes containing infecting viral genomes in various plants. Japan J Microbiol 16: 451-459, 1972.

Proceedings of Symposium :

- 1) 木方 行郎, 町田 治彦 タバコモザイクウイルス感染後のポリゾーム 細胞生物学シンポジウム 21, 33-40, 1970.

### II-3 インターフェロン／ポリ(I)・ポリ(C)関係

- 1) Machida H, Kuninaka A, Yoshino H. Interferon production and resistance to viral infection induced by Poly I·Poly C in chick embryo cells. I. Effect of growth medium. J Japan Microbiol 18: 427-432, 1974.
- 2) Machida H, Kuninaka A, Yoshino H. Interferon production and resistance to viral infection induced by Poly I·Poly C in chick embryo cells. II. Lack of enhancement of DEAEextran. J Japan Microbiol 19: 65-68, 1975.
- 3) Machida H, Kuninaka A, Yoshino H. Relationship between the molecular size of Poly I·Poly C and its biological activity. J Japan Microbiol 20: 71-76, 1975.
- 4) Machida H, Kuninaka A, Yoshino H. Effect of nucleosides on interferon production and development of antiviral state induced by Poly I·Poly C. Microbiol Immunol 23: 643-650, 1979.
- 5) Machida H, Kuninaka A, Yoshino H, Yamada K, Okumura H. Interferon production in human diploid cell strains derived from embryoinLungs. Microbiol Immunol 24: 31-37, 1980.
- 6) 町田 治彦 ラットにおけるインターフェロンの誘発と JTC-19 細胞でのその力値測定 ウイルス 30: 41-46, 1980.
- 7) Machida H, Kuninaka A, Yoshino H. Susceptibility of influenza viruses to interferon and to Poly(I)·Poly(C) determined by the plaque reduction method. Microbiol Immunol 24: 725-731, 1980.
- 8) Machida H, Takezawa J, Kuninaka A, Yoshino H, Nakamura O, Takakura K. Interferon induction and therapy of brain tumor in rats by Poly(ICLC). Microbiol Immunol 26: 353-358, 1982.
- 9) Machida H, Kawade Y, Watanabe Y. Antigenicity of mouse interferons induced I vitro and in vivo by Poly(I)·Poly(C). J Interferon Res 4: 347-353, 1984.
- 10) Nakamura O, Shidara N, Matutani M, Takakura K, Machida H. Phase I-II trials of (Poly ICLC) in malignant brain tumor patients. J Interferon Res 2: 1-4, 1982.

- 11) 中村 治, 設楽 信之, 松谷 雅生, 高倉 公朋, 町田 治彦 Interferon inducer (Poly ICLC)の悪性脳腫瘍治療効果 -基礎と臨床- 脳腫瘍 34: 267-273, 1982.
- 12) 木矢 克造, 北岡 保, 岡本 博文, 原田 廉, 魚住 徹, 峠 哲也, 服部 孝雄, 町田 治彦 実験的脳腫瘍における *Corynebacterium parvum* および Poly ICLC の抗腫瘍効果の検討 Neurol Med Chir 23: 841-848, 1983.
- 13) Ijichi K, Mitamura K, Ida S, Machida H, Shimada K. In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus. J Med Virol 43: 161-165, 1994.
- 14) Ijichi K, Mitamura K, Ida S, Machida H, Shimada K. Comparison of antiviral effects of mismatched double-stranded RNA and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl-5-methyluracil (D-FMAU) against duck hepatitis B virus in vitro. Antiviral Chem Chemother 8: 537-540, 1997.

Review article:

- 1) 町田 治彦 インターフェロンと誘起剤 -その実用化をめぐる最近の話題- 発酵と工業 37: 981-983, 1979.

II-4 薬理／抗腫瘍関係

- 1) Miyazaki S, Imaizumi M, Machida H. Effect of 1-amino-5-bromouracil on GABA<sub>A</sub> receptor complex. Eur J Pharmacol 271: 179-184, 1994.
- 2) Miyazaki S, Imaizumi M, Machida H. Effect of 1-amino-5-bromouracil on brain monoamine metabolism in rats. Pharmacol Biochem Behav 49: 471-475, 1994.
- 3) Imaizumi M, Miyazaki S, Y Watanabe, Machida H. Pharmacological profile of the novel putative anxiolytic agent 1-amino-5-bromouracil. *Arzneim-Forsch/Drug Res* 44 (I): 285-288, 1994.
- 4) Imaizumi M, Miyazaki S, Machida H. Discriminative stimulus properties of diazepam and the novel putative anxiolytic agent 1-amino-5-bromouracil in rats. *Arzneim-Forsch/Drug Res* 44 (II): 1105-1107, 1994.
- 5) Abiru T, Endo K, M, Machida H. Differential vasodilatory action of 2-octynyl-adenosine (TY-146), an adenosine A<sub>2</sub> receptor agonist, in the isolated rat femoral artery and vein. Eur J Pharmacol 281: 9-15, 1995.
- 6) Endo K, M, Abiru T, Machida H, Kasaya Y, Kamata K. Endothelium-derived hyperpolarizing factor does not contribute to the decrease in endothelium-dependent relaxation in the aorta of streptozotocin-induced diabetic rats. *Gen Pharmacol* 26: 149-153, 1995.
- 7) Miyazaki S, Imaizumi M, Machida H. The Effect of anxiolytics and anxiogenics on evaluation of learning and memory in an elevated plus-maze test in mice. *Meth Find Exp Clin Pharmacol* 17: 121-127, 1995.



- 8) Miura S, Tanaka M, Yoshimura Y, Satoh H, Sakata S, Machida H, Matsuda A, Sasaki T. *In vitro* and *in vivo* antitumor activity of a novel nucleoside, 4'-thio-2'-deoxy-2'-methylidencytidine. *Biol Pharm Bull* 19: 1311-1315, 1996.
- 9) Miura S, Yoshimura Y, Endo M, Machida H, Matsuda A, Tanaka M, Sasaki T. Antitumor activity of a novel orally effective nucleoside, 1-(2-deoxy-2-fluoro-4-thio- $\beta$ -D-arabinofuranosyl)cytosine. *Cancer Lett* 129: 103-110, 1998.
- 10) Miura S, Yoshimura Y, Endo M, Satoh H, Machida H, Sasaki T. Comparison of 1-(2-deoxy-2-fluoro-4-thio- $\beta$ -D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity. *Cancer Lett* 144: 177-182, 1999.

### 【第三部:有機合成, 共著】

抗ヘルペス剤開発に関連するもの

- 1) Nakayama C, Machida H, Saneyoshi M. Synthetic nucleosides and nucleotides. XII. Synthesis and antiviral activities of several 1- $\beta$ -D-arabinofuranosyl-5-alkyluracils and their 5'-monophosphates. *J Carbohydrates · Nucleosides Nucleotides* 6: 295-308, 1979.
- 2) Kumagai M, Sakata S, Yamaguchi T, Ikeda K, Machida H. Synthesis of  $^{14}\text{C}$ -labelled 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-mromovinyl)uracil (BV-araU). *J Labelled Compound Radiopharmac.* XXVII: 503-5017, 1989.
- 3) Kano F, Ijichi K, Ashida N, Watanabe Y, Sakata S, Machida H. 5'-*O*-Alkyl and acyl prodrugs of 1- $\beta$ -D-arabinofuranosyl-*E*-5-(2-mromovinyl)uracil. *Antiviral Chem Chemother* 5: 74-82, 1994.

以下合成化学研究者が主体となって行われた研究:

- 4) Saneyoshi M, Morozumi M, Kodama K, Machida H, Kuninaka A, Yoshino H. Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluations of a series of 1- $\beta$ -D-arabinofuranosylcytosine 5'-alkyl or arylphosphates. *Chem Pharm Bull* 28: 2915-2923, 1980.
- 5) Matsuda A, Shinozaki M, Miyasaka, T, Machida H, Abiru T. Palladium-catalyzed cross-coupling of 2-iodoadenosine with terminal alkynes: Synthesis and biological activities of 2-alkynyladenosines. *Chem Pharm Bull* 33: 1766-1769, 1985.
- 6) Abiru T, Miyashita T, Watanabe Y, Yamaguchi T, Machida H, Matsuda A. Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: Adenosine A<sub>2</sub> receptor agonist with potent hypertensive effects. *J Med Chem* 35: 2253-2260, 1992.
- 7) Awano H, Shuto S, Miyashita T, Ashida N, Machida H, Kira T, Shigeta S, Matsuda A. Synthesis and antiviral activities of 5-substitued (2'*S*)-2'-deoxy-2'-*C*-methylidencytidines and -uridines. *Arch Pharm Pharm Med Chem* 329: 66-72, 1996.

- 8) Yoshimura Y, Watanabe M, Satoh H, Ashida N, Ijichi K, Sakata S, Machida H, Matsuda A. A facile alternative synthesis of 4-thioarabinonucleosides and their biological activities. *J Med Chem* 40: 2177-2183, 1997.
- 9) Satoh H, Yoshimura Y, Watanabe M, Ashida N, Ijichi K, Sakata S, Machida H, Matsuda A. Synthesis and antiviral activities of 5-substitued 1-(2-deoxy-2-C- methylen-4-thio- $\beta$ -D-*erythro*-pentofuraosyl)uracils. *Nucleosides • nucleotides*. 17: 65-79, 1998.
- 10) Satoh H, Yoshimura Y, Sakata S, Miura S, Machida H, Matsuda A. Synthesis of L-enantiomers of 4'-thio- $\beta$ -D-arabinofuranosyl pyrimidine nucleosides. *Bioorg Med Chem Lett* 8: 989-992, 1998.
- 11) Yoshimura Y, Endo M, Kitano K, Yamada K, Sakata S, Miura S, Machida H. Synthetic studies on 5-substitued 4'-thiocytidine antineoplastic agents. *Nucleosides • nucleotides*. 18: 815-820, 1999.
- 12) Nagamatsu T, Yamasaki H, Fujita T, Endo K, Machida H. Novel xanthine oxidase inhibitor studies. Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-susbstitued 6-alkylidenehydrazino- or 6-arylmethylidenehydrazino-7*H*-purines and 3-and/or 5-susbstitued 9 *H* -1,2,4-triazolo[3,4-*i*]purines. *J Chem Soc, Perkin Trans 1*, 1999, 3117-3125.
- 13) Kitano K, Machida H, Miura S, Ohru H. Synthesis of novel 4'-C-methyl- pyrimidine nucleosides and their biological activities. *Bioorg Med Chem Lett* 9: 827-830, 1999.
- 14) Yoshimura Y, Kitano K, Yamada K, Sakata S, Miura S, Ashida N, Machida H. Synthesis and biological activities of 2'-deoxy-2'-fluoro-4'-thioarabinofurannosyl- pyrimidine and -purine nucleosides. *Bioorg Med Chem* 8: 1545-1558, 2000.

Proceedings of Symposium :

- 1) Sakata S, Shibuya S, Machida H, Yoshino H, Hirota K, Sennda S, Ikeda I, Mizuo H. Synthesis and antiherpesviral activity of 5-C-substitued uracil nucleosides. *Nucleic Acids Res, Symp Ser* 8: s39-s42, 1980.
- 2) Yoshimura Y, Watanabe M, Sakata S, Ashida N, Miyazaki S, Machida H, Matsuda A. A facile synthesis of 4-thio-arabinonucleosides as potential antiviral agents from D-glucose. *Nucleic Acids Res, Symp Ser* 34: 21-22, 1995.
- 3) Yoshimura Y, Kitano K, Sakata S, Miura S, Ashida N, Machida H, Matsuda A. Synthesis of 2'-deoxy-2'-fluoro-4'-thio-arabinonucleosides as potential antitumor ad antiviral agents from D-glucose. *Nucleic Acids Res, Symp Ser* 35: 15-16, 1996.